Editor’s Pick
Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations (frozen and freeze-dried) of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days. The phase 1 trials looked at safety in a total of 36 patients, and the phase 2 trials, totalling 40 people, found that the vaccines induced antibody responses in all participants within 21 days. Secondary outcomes from the trial also suggest the vaccines also produce a T cell response within 28 days. Large, long-term trials including a placebo comparison, and further monitoring are needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID-19 infection.
No hay comentarios:
Publicar un comentario